Combining immunotherapy with chemotherapy before surgery for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with intrahepatic cholangiocarcinoma (a type of liver bile duct cancer) that can be surgically removed.
- Your tumor is larger than 5 cm, has spread to nearby blood vessels, is multiple (up to 3), has spread to the outer lining of organs, or has suspicious lymph node spread.
- You have not had any prior treatment for this cancer.
- You are at least 18 years old and are in generally good health (ECOG score 0 or 1).
- You do not have serious heart, lung, liver, kidney, or immune problems, and you are not pregnant or breastfeeding.
- You have not had immunotherapy (like PD-1 or CTLA-4 inhibitors) before, and you have no active autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests a new drug combination—cisplatin, gemcitabine (standard chemotherapy), and rilvegostomig (an immunotherapy)—given before and after surgery for a specific type of liver cancer called intrahepatic cholangiocarcinoma. The goal is to reduce the chance of the cancer coming back after surgery.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.